LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (12)
2024
-
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306
2023
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051
-
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645
-
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178
2021
-
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969
2020
-
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
2018
-
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
Mayo Clinic Proceedings, Vol. 93, Núm. 3, pp. 307-320
2017
-
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942
2009
-
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin
Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403